QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
Two-Component Dark Matter Models and the Galactic Center Gamma-Ray Excess: Reconciling the Silence of Dwarf Galaxies
The pursuit of dark matter remains one of the most formidable challenges in modern astrophysics, as this elusive substance constitutes…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
